Genelux Corporation Common Stock (GNLX)

US · Healthcare · Biotechnology

$2.53+8.12%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-9.5M

EPS

$-0.21

EPS estimate

$-0.20

EPS came in at -0.21 against a street estimate of -0.20 — a miss of 5.0%.

Market cap

$112.7M

Forward P/E

0.0

P/B

6.99

Book value

$0.36

EPS (TTM)

$-0.86

52-week high

$8.54

52-week low

$2.29

50-day MA

$2.77

200-day MA

$3.01

Beta

0.56

Analysts rate Genelux Corporation Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $19.00.

Insiders

12.87%

Institutions

31.01%

Fund	Stake
WOODWARD DIVERSIFIED CAPITAL, LLC	5.02%
Vanguard Capital Management, LLC	3.76%
Bleichroeder LP	3.06%
Geode Capital Management, LLC	1.01%
BlackRock Inc	0.90%
Bank of America Corp	0.72%
F.L.Putnam Investment Management	0.62%
Vanguard Fiduciary Trust Co	0.56%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Genelux Corporation Common Stock — free to start.

Data updated 2026-09-18.